Lupin launches cataract surgery pain reduction drug; share price gains
The share touched a 52-week high of Rs 1,429.95 and a 52-week low of Rs 628.10 on January 5, 2024 and March 31, 2023, respectively.
Stay updated with breaking news from Ophthalmic Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The share touched a 52-week high of Rs 1,429.95 and a 52-week low of Rs 628.10 on January 5, 2024 and March 31, 2023, respectively.
Generic Bromfenac Ophthalmic Solution is indicated for the treatment of post operative inflammation and reduction of ocular pain in patients who have under gone cataract surgery.
/PRNewswire/ -- DelveInsight's Myopia Market Insights report includes a comprehensive understanding of current treatment practices, myopia emerging drugs,...
DelveInsight's Graft Versus Host Disease Market...
Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to treat seizure disorders.